AUS
NZ
UK
CA
USA
IND
Roquefort Therapeutics PLC (LSE:ROQ) recently announced that its STAT-6 siRNA has shown effectiveness in an in-vitro model of immunological disease. This development follows direct feedback from potential major pharmaceutical partners.
siRNA technology, which Roquefort is utilizing, works by disrupting the gene's messaging system. The company’s programs target the STAT-6 proteins, which are essential in regulating IL-4 and IL-13 proteins, key players in inflammatory diseases.
Building on the success of its siRNA programs in oncology, Roquefort conducted new experiments to explore the use of siRNA in the STAT-6 inflammation and immunology (I&I) area. This exploration has been validated by industry players like Sanofi and Recludix Pharma.
Preliminary results from these experiments showed a significant reduction in STAT-6 levels compared to controls at various time points. The company plans to present more detailed findings through scientific publications, international conferences, and peer-reviewed journals after completing the tests.
This milestone marks the company’s first result in the ongoing development program within the I&I space. It follows guidance and discussions with major pharmaceutical partners as the company actively seeks an out-licensing agreement for the STAT-6 siRNA program.
CEO Ajan Reginald highlighted the significance of these siRNA results in the I&I field, complementing the strong results previously demonstrated in oncology. He also emphasized the value of the feedback received from potential partners and noted the company’s competitive position, strengthened by completed in-vivo efficacy experiments.
Roquefort’s strategy continues to focus on forming key partnerships with large pharmaceutical companies to solidify the business model. Further updates and milestones in this development are expected in 2024, as noted by Reginald.
